NBI-921352

Phase 2Active

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

SCN8A Developmental and Epileptic Encephalopathy Syndrome

Conditions

SCN8A Developmental and Epileptic Encephalopathy Syndrome

Trial Timeline

Jul 12, 2022 → Mar 1, 2026

NCT ID

NCT05226780

About NBI-921352

NBI-921352 is a phase 2 stage product being developed by Neurocrine Biosciences for SCN8A Developmental and Epileptic Encephalopathy Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT05226780. Target conditions include SCN8A Developmental and Epileptic Encephalopathy Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05493293	Phase 2	Terminated	Nov 9, 2022	Mar 11, 2024	Focal Onset Seizure
NCT05226780	Phase 2	Active	Jul 12, 2022	Mar 1, 2026	SCN8A Developmental and Epileptic Encephalopathy Syndrome

Competing Products

1 competing product in SCN8A Developmental and Epileptic Encephalopathy Syndrome

See all competitors

Product	Company	Stage	Hype Score
NBI-921352 + Placebo	Neurocrine Biosciences	Phase 2	24